Efficacy and safety data for the XEN45 implant at 3 Years: a retrospective analysis
Free Paper Details
First Author: I.Gabbay ISRAEL
Co Author(s): I. Gabbay M. Goldberg F. Allen Z. Lin T. Pearsall S. Ruben
Aim to report efficacy and safety measures for the XEN45 in NHS setting after 36 months follow-up.
University affiliated NHS Foundation Trust in the UK
Retrospective, non-comparative audit of records for patients who underwent an XEN45 between June 2015 and May 2017. Main outcome measures were IOP reduction and number of antihypertensive medications at each timepoint. Failure was defined as further surgery required or removal of XEN. Success was defined as 20% reduction of IOP without additional glaucoma medications or reduction in antihypertensive medications without increase in baseline IOP. Needling rates were assessed and subgroup analysis was performed.
A total of 205 Eyes were included in the study. The main diagnosis was primary open angle glaucoma (84.4%). Standalone procedure was performed for 62.9%. Mean IOP at baseline was 22.6+/-7.0 mmHg. Mean IOP at 24- and 36-months was 14.7+/-3.8 and 14.0+/-2.9 mmHg respectively (p<0.001). Mean number of medications was 2.6+/-1.1 at baseline and 0.5±0.9, 0.6±1.0 medications at 24- and 36-months, respectively (p<0.001). 25% of patients failed at the 36-month timepoint. Needling was required in 36.6% of patients at 36-months. Increased failure rate was found in the non-caucasian ethnic group. No significant adverse events were noted.
XEN45 is a viable, effective and safe procedure after three years of follow-up. Patients should be advised regarding failure rate as well as possible need for bleb revisions and medication use.